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Summary
 Background: The catalytic contribution of four conserved histidines of human coproporphyrinogen oxidase 
(CPO) has been investigated using site-directed mutagenesis to change histidine (H) into alanine 
(A).
 Material/Methods: The wild-type and mutant enzyme forms were analyzed for their ability to utilize coproporphyrin-
ogen-III, mesoporphyrinogen-VI, and harderoporphyrinogen as substrates.
 Results: Wild-type CPO had speciﬁ c activities of 4.9±0.9 nmole product/min/mg for coproporphyrino-
gen-III, 1.7±0.7 nmole product/min/mg for mesoporphyrinogen-VI, and 5.1±1.8 nmole prod-
uct/min/mg for harderoporphyrinogen. The four mutant enzymes were catalytically competent 
with all three substrates, but to varying degrees. The most affected mutant was the H158A enzyme 
which exhibited approximately 50-fold lower activity than wild-type recombinant CPO.
 Conclusions: Thus, His158 of human CPO may have a role in the active site, but none of the conserved histidine 
residues of human coproporphyrinogen oxidase is essential for catalytic activity although changes 
in histidines have been implicated in the disease state hereditary coproporphyria.
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BACKGROUND
Heme and related porphyrins serve as important prosthet-
ic groups in a number of biologically critical proteins, in-
cluding hemoglobin, essential for oxygen transport in the 
blood, and the cytochromes, important in electron trans-
port in the mitochondria of eukaryotic cells. Heme biosyn-
thesis is accomplished through a series of eight enzyme-cata-
lyzed reactions. The Shemin pathway (of plants and animals) 
starts with the relatively simple molecules glycine and suc-
cinyl coenzyme A, and ends with a heme molecule contain-
ing four pyrrole rings linked by methine bridges capable 
of coordinating a ferrous (Fe2+) ion. Coproporphyrinogen 
oxidase (CPO; EC 1.3.3.3) is the sixth enzyme of the heme 
biosynthetic pathway, catalyzing the sequential oxidative 
decarboxylation (Figure 1A) of two propionate groups of 
coproporphyrinogen-III to vinyl groups to yield protopor-
phyrinogen-IX [1,2]. This is a two-step process for which 
the monovinyl intermediate (harderoporphyrinogen) has 
been well established. The enzyme from aerobic organisms 
requires molecular oxygen, but no other known cofactor 
is required. Medlock and Dailey [3] speciﬁ cally and con-
vincingly report that the recombinant human enzyme ex-
pressed in Escherichia coli is not a metalloprotein. In addi-
tion to the authentic substrate, synthetic analogues have also 
been evaluated as substrates for CPO. Mesoporphyrinogen-
VI (Figure 1B) has been shown to be a substrate for this 
enzyme but only undergoes the ﬁ rst oxidative decarbox-
ylation [4,5].
Coproporphyrinogen oxidase deﬁ ciency in humans leads 
to the disease state hereditary coproporphyria (HCP). In 
HCP, CPO activity is often signiﬁ cantly reduced, and afﬂ ict-
ed HCP individuals suffer from neurological disturbances 
and cutaneous photosensitivity [6,7]. The gene encoding 
human CPO is located on chromosome 9 [8] and genome 
sequencing efforts have revealed mutations in the CPO gene 
that lead to HCP [9,10]. In mammals, CPO is expressed as 
a 40 kDa precursor, and contains an amino terminal mito-
chondrial targeting signal. After proteolytic processing, the 
protein is present as a mature 37 kDa form [10–12]. CPO is 
reported to be located in the intermembrane space of the 
mitochondria and possesses the ability to associate with the 
mitochondrial inner membrane [1,13].
Coproporphyrinogen oxidase from both prokaryote and 
eukaryote organisms has been studied, including yeast 
[14,15], chicken erythrocytes [16], mouse liver [17], and 
bovine liver [18]. In addition to the isolation of CPO from 
bovine liver, mouse liver, and yeast, recombinant human 
[3] and mouse CPO [19] have been puriﬁ ed. Studies in-
vestigating the chemical modiﬁ cation of speciﬁ c amino ac-
ids have implicated tyrosine, arginine, histidine and lysine 
residues as playing a signiﬁ cant role in catalysis or protein 
structure [16,20,21].
Modern molecular biological techniques and genome se-
quencing projects have facilitated the inﬂ ux of a tremen-
dous amount of nucleotide sequence data. A search of cur-
rent nucleotide and protein databases reveals more than 
20 putative CPO sequences, from organisms as diverse as 
mammals, plants, insects, yeast, enterobacteria, and cyano-
bacteria. An alignment of the available CPO amino acid 
sequences is useful for assessing the common evolution-
ary origin of the enzymes in this family. Certain amino ac-
ids have been conserved in evolution, suggesting a critical 
role in the function of the protein. Among the conserved 
amino acids of aerobic CPO are four histidines, an amino 
acid previously implicated as potentially critical for catalysis 
by chemical modiﬁ cation studies [21]. Shown in Figure 2 is 
an alignment of CPO amino acid sequences from seven rep-
resentative organisms. Among these seven sequences, the 
overall amino acid sequence identity is 26%. Identical ami-
no acids are shaded in black while the four conserved his-
tidines at positions 148, 158, 197, and 227 are indicated by 
the asterisks. The human and the mouse genes are highly 
conserved with both having the four conserved histidines 
as compared by Medlock and Dailey [3].
Catalysis by CPO is poorly understood at the molecular level. 
The roles of speciﬁ c amino acids in catalysis by human CPO 
have not yet been elucidated. Histidines are common pro-
ton donors and acceptors in biological catalysis, and there-
fore their involvement in the catalytic mechanism of CPO is 
reasonable to assess. Conserved His158 was previously pro-
posed to play a critical role in metal coordination in mouse 
CPO [19]. Subsequently, however, human CPO was found 
to not require metal ions for catalysis [3].
This study investigated the contribution of four conserved 
histidines to catalysis by human coproporphyrinogen oxi-
dase by substituting histidine (H) at position 148, 158, 197, 
or 227 with alanine (A) using site-directed mutagenesis. 
The wild-type and mutant forms of the recombinant en-
zyme were expressed in E. coli, puriﬁ ed to electrophoretic 
homogeneity, and analyzed for the ability to utilize copro-
porphyrinogen-III, harderoporphyrinogen, and mesopor-
phyrinogen-VI as substrates for catalysis. Use of the three 
different substrates allows for comparison of rates for the 
ﬁ rst and second decarboxylations. For the most interesting 
histidine mutant (H158A), enzyme kinetics were also car-
ried out to determine Km, Vmax, kcat and kcat/Km, and these 
were compared to the values obtained for the recombinant 
human wild-type enzyme.
MATERIAL AND METHODS
Material
The polymerase chain reaction was performed using oligo-
nucleotide primers and Platinum Pfx DNA Polymerase from 
Invitrogen. Expression vector pET21d was obtained from 
Novagen. Restriction endonucleases were purchased from 
New England Biolabs. T4 DNA Ligase was from Promega and 
isopropyl-b-D-thiogalactoside (IPTG) was from Eppendorf. 
Clontech was the source of TALON metal afﬁ nity resin. 
Protease inhibitors were from Sigma. Qiaprep spin mini-
prep and Qiaex II gel extraction kits were from Qiagen. 
Automated ﬂ uorescent sequencing was performed on an ABI 
377 sequencer using a BigDye terminator DNA sequencing 
kit from Applied Biosystems. Tryptone, yeast extract, sodium 
chloride, chloramphenicol, and ampicillin were purchased 
from Fisher. The Protein Assay Kit was from Bio-Rad.
Construction of expression vector pET21d-CPO
The pET inducible protein expression system was 
used for large-scale production of recombinant CPO. 
Basic Research Med Sci Monit, 2007; 13(1): BR1-10
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Figure 1.  Reactions catalyzed by coproporphyrinogen oxidase. (A) conversion of coproporphyrinogen-III to protoporphyrinogen-IX via 
harderoporphyrinogen, a monovinyl intermediate. (B) conversion of mesoporphyrinogen-VI to the monovinyl product.
A
B
Med Sci Monit, 2007; 13(1): BR1-10 Gitter SJ et al – Histidines of coproporphyrinogen oxidase
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The NcoI/HindIII fragment from expression vector 
pHHCPO [3] was subcloned into the multiple cloning site 
of pET21d. This resulted in expression of the cDNA encod-
ing CPO to be under control of the lac operon. Production 
of recombinant CPO is induced by the addition of IPTG.
Site-directed mutagenesis
Site-directed mutagenesis was performed using the PCR-me-
diated overlap extension method [22] utilizing three gener-
al oligonucleotides and a fourth mutagenic oligonucleotide. 
Oligonucleotide #1 had the sequence 5’-CGCGGATCCAT
GGCTCACCATCACCATCACC-3’ and contained a NcoI re-
striction enzyme site (underlined). Oligonucleotide #2 had 
the sequence 5’-TTGCAATACGGAACTTCCAGAATTTCA
GCTTCTTTGG-3’ and contained a 5’ non-complementa-
ry overhang of 10 nucleotides. Oligonucleotide #3 had the 
sequence 5’-GGGGTACCAAGCTTATTCTGCCTGCATCA
ACGC-3’ and contained a HindIII restriction enzyme site 
(underlined). Mutagenic oligonucleotides had the follow-
ing sequences (alanine codons underlined): H148A; 5’-GG
GCGTGAGTTCTGTTATCGCCCCCAAGAATCCTCATG-3’, 
H158A; 5’-CCTCATGCTCCTACGATCGCGTTCAACTACA
GATAC-3’, H197A; 5’-GAAGACGCTGTCCATTTTGCGCG
H. sapiens  82 ER-KEGGGGISCVLQDGCVFEKAGVSISVVHGNLSEEAAKQMRSRGKVLKTKD------- 
A. thaliana 114 SR-PGGGGGISRVLQDGNVFEKAGVNVSVVYGVMPPEAYRAAKGSASDQKP--------- 
C. reinhardtii  92 TR-PGGGGGISRVLQDGNVWEKAGVNVSVVYGTMPPEAYRAATGNAEKLKNKGDG----- 
D. melanogaster 120 ER-PEGGGGITCVLQDGDVFEKAGVNISVVTGSLPPAAVQQMRARGKNLKEG-------- 
S. cerevisiae  45 TRGNDGGGGTSMVIQDGTTFEKGGVNVSVVYGQLSPAAVSAMKADHKNLRLPEDPKTGLP 
E. coli  37 QR-EAGGGGRSRVLRNGGVFEQAGVNFSHVHGEAMPASATAHRPELAGRSF--------- 
Synechocystis sp.  54 QR-EEGGGGRSRVLADGDFLEQGGVNFSEVWGKSLPPSILKQRPEAEGHEF--------- 
H. sapiens  134 --GKLPFCAMGVSSVIHPKNPHAPTIHFNYRYFEVEEADGNKQ----WWFGGGCDLTPTY
A. thaliana 164 --GPVPFFAAGVSSVLHPKNPFAPTLHFNYRYFETDAPKDVPGAPRQWWFGGGTDFTPAY
C. reinhardtii 146 --GRVPFFAAGISSVMHPRNPHCPTMHFNYRYFETEEWNGIP---GQWWFGGGTDITPSY
D. melanogaster 171 --ASLPFFASGVSAVIHPRNPHVPTIHFNYRYFEVETAKGEKQ----WWFGGGTDLTPYY
S. cerevisiae 105 VTDGVKFFACGLSMVIHPVNPHAPTTHLNYRYFETWNQDGTPQT---WWFGGGADLTPSY
E. coli  87 -------EAMGVSLVVHPHNPYVPTSHANVRFFIAEK----PGADPVWWFGGGFDLTPFY
Synechocystis sp. 104 -------YATGTSMVLHPKNPYIPTVHLNYRYFEAG---------PVWWFGGGADLTPYY
                                        *         * 
H. sapiens  188 LNQEDAVHFHRTLKEACDQHGPDLYPKFKKWCDDYFFIAHRGERRGIGGIFFDDLD---- 
A. thaliana 222 IFEEDVKHFHSIQKQACDKFDPSFYPRFKKWCDDYFYIKHRDERRGLGGIFFDDLN---- 
C. reinhardtii 201 VVPEDMKHFHGTYKAVCDRHDPAYYEKFRTWCDEYFLIKHRGERRGLGGIFFDDLN---- 
D. melanogaster 225 LCEKDASHFHQTLKSACDEHDPTYYPRFKKWCDDYFRIKHRNESRGIGGIFFDDID---- 
S. cerevisiae 162 LYEEDGQLFHQLHKDALDKHDTALYPRFKKWCDEYFYITHRKETRGIGGIFFDDYD---- 
E. coli 136 GFEEDAIHWHRTARDLCLPFGEDVYPRYKKWCDEYFYLKHRNEQRGIGGLFFDDLN---- 
Synechocystis sp. 148 PFAEDAAHFHHTLKNACDQTHGEFYPVFKRWCDEYFYLKHRQEMRGIGGIFFDYQDGNAP 
                                 *                             * 
H. sapiens  244 ----------------------SPSKEEVFRFVQSCARAVVPSYIPLVKKHCDDSFTPQE 
A. thaliana 278 ----------------------DYDQEMLLSFATECANSVVPAYIPIVEKRKDMEFTEQH 
C. reinhardtii 257 ----------------------DRNPEDILKFSTDAVNNVVEAYCPIIKKHMNDPYTPEE 
D. melanogaster 281 ----------------------SPNQEAAFNFVSSCARAVIPSYVPLVRKHKNREYGNNE 
S. cerevisiae 218 ----------------------ERDPQEILKMVEDCFDAFLPSYLTIVKRRKDMPYTKEE 
E. coli 192 ----------------------TPDFDRCFAFMQAVGKGYTDAYLPIVERRKAMAYGERE 
Synechocystis sp. 208 LYRGPDPNGPAAQYSNQLAPIEPLGWEDLFSFAQRCGRAFLPAYSPIVEKRRNTEYGDRQ 
H. sapiens  282 KLWQQLRRGRYVEFNLLYDRGTKFGLFTPGSRIESILMSLPLTARWEYMHSPSENSKEAE 
A. thaliana 316 KAWQQLRRGRYVEFNLVYDRGTTFGLKTGG-RIESILVSLPLSARWEYDHKPEEGTEEWK 
C. reinhardtii 295 KEWQQIRRGRYVEFNLVYDRGTTFGLKTGG-RIESILMSMPQTASWLYDHQPKAGSPEAE 
D. melanogaster 319 RQWQLLRRGRYVEFNLIYDRGTKFGLYTPGARYESILMSLPLHARWEYMHEPKSQSEEGK 
S. cerevisiae 256 QQWQAIRRGRYVEFNLIYDRGTQFGLRTPGSRVESILMSLPEHASWLYNHHPAPGSREAK 
E. coli 230 RNFQLYRRGRYVEFNLVWDRGTLFGLQTGG-RTESILMSMPPLVRWEYDYQPKDGSPEAA 
Synechocystis sp. 268 RQFQLYRRGRYVEFNLVYDRGTIFGLQTNG-RTESILMSLPPLVRWQYCYSPEAGSPEAE 
Figure 2.  Alignment of amino acid sequences of coproporphyrinogen oxidase from representative organisms. The amino acid sequence from 
amino acids 82-341 of human coproporphyrinogen oxidase (Homo sapiens; accession BAA04033) is compared to coproporphyrinogen 
oxidase from a plant (Arabidopsis thaliana; accession AAF86536), a green algae (Chlamydomonas reinhardtii; accession AAD28475), fruit 
fl y (Drosophila melanogaster; accession AAD46837), baker’s yeast (Saccharomyces cerevisiae; accession CAA89966), an enterobacteria 
(Escherichia coli; accession BAA16325), and a cyanobacteria (Synechocystis sp.; accession BAA16863). Conserved amino acids are boxed in 
black. The conserved histidines at positions 148, 158, 197, and 227 are boxed in gray and indicated by an asterisk. Sequence alignment 
was generated using the BCM Search Launcher at Baylor College of Medicine (http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.
html) and the Boxshade server (http://www.ch.embnet.org/software/BOX_form.html).
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CACTCTGAAGGAGGC-3’, H227A; 5’-GATTACTTCTTTAT
AGCCGCCCGTGGAGAGCGGCGGGGC-3’.
PCR was run using the following thermocycle parameters: 
94°C 30 seconds, 55°C 30 seconds, 72°C 1 minute. Thirty 
cycles were run in each PCR reaction. Three PCR reactions 
were run for construction of each mutated cDNA. PCR reac-
tion 1 employed oligonucleotides #1 and #2. Oligonucleotide 
#1 anneals to the bottom strand (non-coding strand) at the 
5’ end of the cDNA. Oligonucleotide #2 anneals to the top 
strand (coding strand) near the 3’ end of the gene and con-
tains 10 mismatched nucleotides at the 5’ end. PCR reac-
tion 1 resulted in a DNA fragment that has a mismatch at 
one end encoded in oligo 2, preventing extension from its 
3’ end in subsequent PCR reactions, providing the basis for 
selection of mutant CPO clones. PCR reaction 2 used oligo-
nucleotide #3 and the desired mutagenic oligonucleotide, 
and resulted in a DNA fragment complementary to the PCR 
reaction 1 fragment. Template DNA for PCR 1 and PCR 2 
was pET21d-CPO, the wild-type human CPO cDNA cloned 
into pET21d. The encoded wild-type CPO lacked the ami-
no terminal 33 amino acids that serve as a mitochondrial 
targeting signal, and contained the amino terminal amino 
acid sequence Met-Ala-His-His-His-His-His-His preceding 
proline 34, serving as a 6x-His-tag for afﬁ nity puriﬁ cation 
using a metal afﬁ nity column. Following PCR 1 and 2, 10 μl 
of each PCR reaction was run on a 0.7% agarose gel. The de-
sired DNA fragments were puriﬁ ed from the gel and com-
bined in a third PCR reaction employing oligonucleotides 
#1 and #3. Each PCR product was digested with restriction 
endonucleases NcoI and HindIII, followed by ligation with 
NcoI/HindIII-digested pET21d. Each cDNA was sequenced 
to verify the desired mutation had been incorporated.
Expression and puriﬁ cation of His-tagged wild-type and 
mutant CPO proteins
Escherichia coli strain BL21(DE3)RIL (Stratagene) was used as 
expression host. One liter cultures containing pET21d-CPO 
were grown in a shaking incubator at 37°C and 300 rpm to an 
optical density of 0.8 at 600 nm in LB medium containing 50 
μg/ml ampicillin and 34 μg/ml chloramphenicol. Induction 
of protein expression was accomplished by the addition of 
1 mM IPTG, followed by incubation at 37°C and 300 rpm 
shaking for 3 hours. Cells expressing wild-type and mutant 
forms of CPO were harvested by centrifugation at 4,620 × g 
for 5 minutes. A considerable percentage of mutant enzyme 
H197A was present in inclusion bodies when expression was 
performed at 37°C. Therefore, upon induction with IPTG, 
bacterial cultures expressing H197A were grown at 25°C, sig-
niﬁ cantly increasing the amount of soluble protein.
Bacterial cell pellets were resuspended in 40 ml CPO lysis buf-
fer (50 mM NaxPO4, 300 mM NaCl, 50 mM Tris, pH 7) con-
taining 2.5 μg/ml leupeptin, 2 μg/ml chymostatin, 2 μg/ml 
pepstatin, 1 μg/ml antipain, 10 μg/ml p-aminobenzamidine, 
10 μg/ml benzamidine, and 0.2 mM phenylmethylsulfonylﬂ u-
oride. Cells were lysed using a French Pressure cell at 20,000 
psi, therefore addition of the detergent n-octyl-b-D-glucopy-
ranoside, used previously by Medlock and Dailey [3], was un-
necessary. We observed similar enzymatic activity for CPO in 
the presence or absence of detergent (data not shown). After 
centrifugation (100,000 × g for 30 min) the supernatant was 
passed through a 4 ml column of TALON metal afﬁ nity res-
in. The column was washed with 50 ml CPO lysis buffer, fol-
lowed by 50 ml CPO lysis buffer containing 20 mM imidaz-
ole. Protein elution was accomplished by passing 10 ml of 
CPO lysis buffer containing 250 mM imidazole (adjusted to 
pH 7) through the column. Fractions of approximately 1 ml 
each were collected. The protein concentration of each frac-
tion was determined by the method of Bradford [23]. In all 
cases, enzyme activities were measured for the supernatant 
fraction as well as all fractions eluted from the column; ac-
tivities for these various fractions were comparable for wild-
type and mutant enzymes (data not shown).
Substrate preparation
For enzyme assays, three different substrates (copropor-
phyrinogen-III, harderoporphyrinogen, and mesopor-
phyrinogen-VI) were used. The ﬁ rst is the authentic sub-
strate, while harderoporphyrinogen is the intermediary 
monovinyl metabolite (Figure 1A). Mesoporphyrinogen-
VI (meso’gen-VI) (Figure 1B) has been previously used to 
assess the ability of chicken CPO to recognize variations in 
ring substituents [4,5,24]. Use of the three substrates thus 
allows for the relative comparison of rates for the ﬁ rst and 
second oxidative decarboxylation for both wild-type and 
mutant enzymes. The substrates were prepared from the 
corresponding porphyrin tetramethyl esters by treatment 
overnight with 8.3 M HCl and reduction with 3% sodium 
amalgam as previously reported [5,24]. Coproporphyrin-
III tetramethyl ester was purchased from Aldrich Chemical 
(Milwaukee, WI). Harderoporphyrin trimethyl ester and 
mesoporphyrin-VI dimethyl ester were synthesized from 
a,c-biladiene intermediates [24–26]. In all cases, the re-
duced porphyrinogens were used immediately following 
reduction and quantitated spectrophotometrically at 406 
nm in 8.3 M HCl. For time course experiments, substrates 
were used in the range of 0.7 to 1 μM as the ﬁ nal concen-
tration in the enzyme incubations, concentrations above 
the Km value for coproporphyrinogen III of 0.3 μM report-
ed in this work (Table 1).
Substrate Km (μM) kcat (min
–1) kcat/Km
Wildtype Enzyme
Coproporphyrinogen-III  0.3  3.6  12.0
Harderoporphyrinogen  1.2  7.9  6.6
H158A Mutant Enzyme
Coproporphyrinogen-III  0.15  0.015  0.10
Harderoporphyrinogen  0.15  0.023  0.15
Table 1.  Kinetic constants of coproporphyrinogen oxidase for total product accumulated.
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Enzyme assay
Recombinant human CPO was assayed using the micro pro-
cedure reported by Jones et al. [27]. Brieﬂ y, puriﬁ ed re-
combinant human CPO (300 μl of 50 μg/ml) was incubat-
Figure 3.  (A) Purifi cation of 6x-His-tagged wildtype CPO expressed 
in E. coli. Lane 1: molecular weight standards (kDa), Lane 2: 
100,000 × g supernatant (20 mg), Lane 3: metal affi  nity 
column non-binding fraction (20 mg), Lanes 4–8: 250 mM 
imidazole metal affi  nity column elution (1 μg, 2 μg, 4 μg, 
8 μg, and 12 μg, respectively). (B) Purifi cation of 6x-His-
tagged CPO mutant enzyme H148A expressed in E. coli. Lane 
1: molecular weight standards (kDa), Lane 2: 100,000 × g 
supernatant (20 μg), Lane 3: metal affi  nity column non-
binding fraction (20 μg), Lanes 4 and 5: 250 mM imidazole 
metal affi  nity column elution (2 μg and 4 μg, respectively). 
(C) Purifi cation of 6x-His-tagged CPO mutant enzyme H158A 
expressed in E. coli. Lane 1: molecular weight standards 
(kDa), Lane 2: 100,000 × g supernatant (20 μg), Lane 3: 
metal affi  nity column non--binding fraction (10 μg), Lanes 
4 and 5: 250 mM imidazole metal affi  nity column elution (2 
μg and 4 μg, respectively). (D) Purifi cation of 6x-His-tagged 
CPO mutant enzyme H197A expressed in E. coli. Lane 1: 
molecular weight standards (kDa), Lane 2: whole cell lysate, 
Lane 3: 100,000 × g pellet, Lane 4: 100,000 × g supernatant 
(20 μg), Lane 5: metal affi  nity column non-binding 
fraction (20 μg), Lanes 6 and 7: 250 mM imidazole metal 
affi  nity column elution (0.5 μg and 4 μg, respectively). (E) 
Purifi cation of 6x-His-tagged CPO mutant enzyme H227A 
expressed in E. coli. Lane 1: molecular weight standards 
(kDa), Lane 2: 100,000 × g supernatant (20 μg), Lane 3: 
metal affi  nity column non-binding fraction (20 μg), Lane 4: 
metal affi  nity column 20 mM imidazole wash fraction, Lanes 
5 and 6: 250 mM imidazole metal affi  nity column elution (4 
μg and 2 μg, respectively).
A
B
C
D
E
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ed with the freshly prepared substrates in the dark at 37°C. 
For each prepared mutant, both wild-type and mutant en-
zymes were incubated under the same conditions so that 
data are reported relative to wild-type activity. For each ex-
periment, time courses for both wild-type and mutant en-
zymes were performed. Speciﬁ c activities (nmole product 
formed/min/mg protein) for the three different substrates 
were determined under apparent initial velocity conditions. 
Reactions were stopped by the addition of acetic acid: ethyl 
acetate (3:7 v/v) and extracted into the ethyl acetate layer 
as reported previously [27]. The porphyrins were converted 
to their methyl esters and the substrate and product were 
separated by HPLC using a partisil silica column and a mo-
bile phase solvent of ethyl acetate: cyclohexane (35:65 v/v 
for coproporphyrin-III and harderoporphyrin and 3:7 v/v 
for mesoporphyrin-VI). Eluting porphyrins were detected 
at 404 nm and percent product calculated from the inte-
grated peak areas. When using coproporphyrinogen-III as 
substrate, total product was calculated as the sum of the mo-
novinyl and divinyl products. In all cases, results were com-
pared to zero time incubations to correct for background.
Kinetics with wild-type CPO and H158A enzyme
Both the wild-type enzyme and the H158A mutant enzyme 
were assayed under apparent initial velocity conditions with 
two different substrates (coproporphyrinogen-III and har-
deroporphyrinogen) at various concentrations from 0.1 to 
2.4 μM. Incubations were done under standard conditions 
with 7.5 μg enzyme per incubate.
RESULTS
Expression and puriﬁ cation of His-tagged human wild-
type (WT) and mutant CPO proteins
To assess the level of endogenous bacterial activity, E. coli 
cultures expressing a non-related recombinant enzyme 
(Pseudomonas mevalonii HMG-CoA reductase) were ana-
lyzed. No coproporphyrinogen oxidase activity was detect-
able in the 250 mM imidazole elution fraction from the met-
al afﬁ nity column (where the recombinant enzyme elutes). 
Bacterial CPO activity was found in the 100,000 × g super-
natant fraction and in the fraction that did not bind to the 
afﬁ nity column. Expression of recombinant wild-type hu-
man CPO in E. coli increased the activity in the superna-
tant fraction by approximately 500-fold compared to the 
level of endogenous bacterial CPO activity in the control 
culture. For all histidine mutants, CPO enzyme activities 
in the 250 mM elution fraction were substantially higher 
than that obtained using the Pseudomonas mevalonii HMG-
CoA reductase fractions.
The inducible pET expression system (Novagen) resulted 
in a large yield of recombinant wild-type CPO that was easily 
puriﬁ ed using afﬁ nity chromatography. An SDS-PAGE anal-
ysis of puriﬁ cation fractions is shown in Figure 3A. Levels of 
recombinant wild-type CPO were estimated to be as high as 
30% of the total cellular protein. Yields of electrophoreti-
cally pure wild-type CPO were as high as 95 mg per liter of 
bacterial culture. The large amounts of pure CPO obtain-
able using this expression system should facilitate future 
studies of human CPO using biophysical methods that re-
quire large amounts of pure protein. For all mutants, elec-
trophoretic purity was also evaluated, with results very simi-
lar to those shown for the wild-type enzyme with substantial 
amounts of enzyme found in the soluble fraction and in the 
250 mM elution fraction (Figure 3 B–E).
Catalysis by recombinant human CPO (wild-type)
For the human wild-type enzyme, the speciﬁ c activities 
(nmole product/min/mg protein) using the three differ-
ent substrates were 4.9±0.9 for coproporphyrinogen-III, 
5.1±1.8 for harderoporphyrinogen, and 1.7±0.7 for meso-
porphyrinogen-VI (mean ±SD for n=5). Our data indicate 
that the mesoporphyrinogen-VI is used much less efﬁ ciently 
by the wild-type enzyme relative to the other two substrates. 
This is in contrast to the chicken enzyme which apparent-
ly uses mesoporphyrinogen-VI and coproporphyrinogen-
III with equal ability [24]. Using coproporphyrinogen-III, 
there is little accumulation of the monovinyl product (har-
deroporphyrinogen) relative to the divinyl product (proto-
porphyrinogen-IX) at any incubation time, suggesting that 
the ﬁ rst decarboxylation is a slower process than the second 
and thus may be the rate limiting event.
Catalysis by recombinant human CPO mutant enzymes
For the four different histidine mutants, the ability to use 
the three different substrates is indicated in Figure 4 as per-
cent of wild-type speciﬁ c activity. Mutant enzyme H148A, 
though less active relative to wild-type enzyme under iden-
tical incubation conditions, still retained 39% of wild-type 
activity for the overall conversion of coproporphyrinogen-
III to protoporphyrinogen-IX. This is similar to the reduced 
activity seen with harderoporphyrinogen as substrate (43% 
of wild-type). A decrease in activity was also apparent for 
the ﬁ rst oxidative decarboxylation using mesoporphyrino-
gen-VI (21% of wild-type). This decrease in activity relative 
to wild-type suggests His148 is not directly involved in ca-
talysis but may play a structural role in CPO.
Mutant enzyme H197A also retained the ability to efﬁ cient-
ly catalyze the overall reaction (conversion of coproporphy-
rinogen-III to protoporphyrinogen-IX). The ability to cat-
alyze the overall reaction at only 50% of the wild-type rate 
is likely due to a decrease in the ability to perform the ﬁ rst 
oxidative decarboxylation, as estimated utilizing mesopor-
phyrinogen-VI as substrate. The second oxidative decarbox-
ylation step was not impaired, with mutant enzyme H197A 
retaining 100% of the wild-type activity using harderopor-
phyrinogen as substrate.
Interestingly, mutant enzyme H227A catalyzed the conver-
sion of coproporphyrinogen-III to protoporphyrinogen-
IX at a rate almost twice that of the wild-type enzyme. The 
increase in speciﬁ c activity, relative to wild-type enzyme, of 
the H227A mutant is illustrated by the ability of the mu-
tant enzyme to use all three substrates better than wild-
type enzyme. With the other three mutants, as well as the 
wild-type human CPO, the ﬁ rst oxidative decarboxylation 
is the apparent rate limiting step for catalysis. However, for 
H227A the ﬁ rst oxidative decarboxylation no longer ap-
pears to be the rate limiting step when His227 is replaced 
by alanine since the incubations with mesoporphyrinogen-
VI yielded higher speciﬁ c activities than with either of the 
other two substrates.
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The mutant enzyme most catalytically impaired was that for 
which His 158 was replaced by alanine. The ability of the 
H158A mutant enzyme to catalyze the conversion of copro-
porphyrinogen-III to protoporphyrinogen-IX was decreased 
some 50-fold. This decrease, while large, still reﬂ ects con-
siderable enzyme activity, as the puriﬁ ed mutant enzyme 
retained activity per mg of enzyme approximately 100-fold 
greater than the baseline value for a control puriﬁ cation 
procedure conducted on cells expressing an unrelated pro-
tein, Pseudomonas mevalonii HMG-CoA reductase. The de-
crease in speciﬁ c activity was attributable to impairment of 
both the ﬁ rst and second oxidative decarboxylations, with 
the ﬁ rst catalyzed at 9% of the wild-type and the second at 
14% of the wild-type. In a previous study conducted using 
recombinant mouse CPO, His158 was proposed to be essen-
tial for coordination of a metal ion, most likely Cu2+ [19]. 
Crude cell extracts of bacterial cultures, in which His 158 
had been mutated to alanine in mouse CPO, resulted in no 
detectable activity. Analysis of recombinant human CPO by 
Medlock and Dailey, however, conclusively determined met-
al ions were not necessary for catalysis [3].
There was little difference in the Km value for copropor-
phyrinogen III for mutant enzyme H158A as compared to 
wild-type enzyme as shown in Table 1. However, when har-
deroporphyrinogen was used as substrate, there was an ap-
parent difference in the Km value of the wild-type enzyme 
and the mutant. This suggests alanine at position 158 has a 
modest effect on the ability of CPO to bind substrate. There 
was, however, a more substantial effect on the kcat value that 
was especially evident with harderoporphyrinogen as sub-
strate. The catalytic efﬁ ciency (kcat/Km) of the wild-type en-
zyme was substantially higher than that of the H158A mu-
tant (Table 1) using either substrate.
An interesting consequence of replacing histidine 158 with 
alanine was the relative ability of CPO to catalyze formation 
of the monovinyl product (harderoporphyrinogen) relative 
to the divinyl product protoporphyrinogen IX. In Figure 5 
the ratio of divinyl product to monovinyl product using cop-
roporphyrinogen-III is shown for the human wild-type en-
zyme and compared to the values for the various histidine 
mutants. The H148A, H197A and H227A mutants all have 
similar abilities to produce a similar ratio of divinyl to mo-
novinyl product as wild-type. However, the H158A mutant 
yielded a much different ratio for these two products, pro-
ducing substantially more of the monovinyl product than 
the divinyl product. It would be of interest to evaluate these 
histidine mutants using the A ring isomer coproporphy-
rinogen-IV (C-IV) for which it was previously shown that 
increased levels of C-IV may be able to compete with the 
authentic substrate. Such competition has important impli-
cations for clinical porphyrias [28].
DISCUSSION
Location of conserved histidines 148, 197, and 227 in the 
three-dimensional structure of human CPO
During completion of the work described here, three-dimen-
sional structures of both Saccharomyces cerevisiae [29] and Homo 
sapiens [30] coproporphyrinogen oxidase were determined. 
In each case, the structure of CPO was reported to be dimer-
ic. Phillips et al. [29] report the yeast CPO active-site is likely 
a deep cleft lined by conserved amino acid residues and each 
monomer has its own active-site. His158 of human CPO ap-
pears to be His133 of yeast CPO (in the S5 secondary struc-
tural region). The authors locate this region as perhaps one 
side of the active site cleft. In human CPO [30], each mono-
mer contains a central 7-stranded antiparallel beta sheet with 
multiple helices present on each side of the sheet. A mole-
cule of citrate is present in the crystallized enzyme, occupy-
ing a cleft near the dimer interface. The coordinate ﬁ le for 
the CPO monomer (PDB: 2AEX) was downloaded from the 
protein database and analyzed, allowing us the opportunity 
to probe the structural basis for our observations upon mu-
tagenesis of the conserved histidines. Two of the conserved 
histidines mutated in this study (His148 and His197) are pres-
ent within the interior of the monomer. His148 is found at 
the C-terminal end of b4 of the central seven-stranded beta 
sheet while His197 is in the middle of a5, projecting from 
this alpha helix into the interior of the monomer. His148 and 
His 197, therefore, form a variety of atomic interactions that 
are likely to play a role in maintaining the structural integ-
rity of the monomer structure. These observations support 
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our data that His148 and His197 are not involved in cataly-
sis. Histidine 227 is the only one of the four conserved histi-
dines investigated in this study that is present on the surface 
of the monomer, and is thought to be involved in monomer-
monomer interaction at the dimerization surface in addition 
to the atomic interactions within a single monomer.
Location of histidine 158 in the three-dimensional 
structure of human CPO and possible role in catalysis
Two recent catalytic mechanisms for CPO have proposed a 
base-catalyzed oxidative decarboxylation [30,31]. Though 
the mechanisms differ with respect to the proton abstracted 
and the nature of the intermediates, each requires an amino 
acid that acts as a base in the active site. His158, present at 
the N-terminal end of b5 of the seven-stranded beta sheet, 
is present in the putative active site electrostatic cleft con-
taining a citrate molecule. The proximity of His158 to ci-
trate led to the proposal that this amino acid may perform 
an essential catalytic function, possibly as a base to abstract 
a proton from coproporphyrinogen III, generating a carb-
anion [30] or a pyrrolic anion [31]. The prediction that 
His158 is present in the active site of CPO is supported by 
our data, since H158A retained less than 5% of the wild-
type activity. However, the signiﬁ cant remaining activity in 
H158A suggests that His158, though important for cataly-
sis, is not essential. Our observation that the H158A mutant 
enzyme retains signiﬁ cant activity is contrary to Kohno et 
al. [19] in which the H158A mutant of mouse CPO was re-
ported to have no activity. This discrepancy may be due to 
the inability of Kohno et al. to detect the low level of activ-
ity since enzymes were assayed in unpuriﬁ ed cytosolic frac-
tions, not as puriﬁ ed, highly concentrated samples. In our 
case we had to add a signiﬁ cantly greater quantity of H158A 
enzyme to each assay to reliably measure activity, made pos-
sible by a highly puriﬁ ed, concentrated enzyme sample. In 
addition, Kohno et al. showed that mouse CPO contains 
copper and His158 was directly implicated in copper coor-
dination since mouse CPO mutant enzyme H158A displayed 
a very low copper content relative to wild-type enzyme. In 
contrast to the mouse enzyme, human CPO has been shown 
to not be a metalloenzyme [3], therefore His158 does not 
function to coordinate copper.
CONCLUSIONS
Our data show that mutant forms of human coproporphy-
rinogen oxidase, where a conserved histidine residue at ei-
ther position 148, 158, 197, or 227 is replaced by alanine, 
are still catalytically competent. The level of activity remain-
ing in the mutant forms of this enzyme is several orders of 
magnitude greater than expected if only the histidine ami-
no acid side chain was directly participating in catalysis. 
Therefore, we conclude that these conserved histidine res-
idues are not absolutely essential for the catalytic mecha-
nism of human coproporphyrinogen oxidase but are like-
ly to be important in maintaining the native conformation. 
The large decrease in activity of the H158A mutant enzyme 
supports the hypothesis that this amino acid is at or near 
the active site of the enzyme, possibly reﬂ ecting an impor-
tant role in maintaining the active site architecture of the 
native enzyme. However, until the crystal structure of CPO 
has been solved as an enzyme-substrate complex, the roles 
of active site amino acids remain ambiguous.
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